EpiTech MAG
Noninvasive Magnetic Therapy for Dry Eye Disease
Company Overview
Snapshot
Founded in March 2015 by Itzik Ronen, EpiTech MAG operates with 1–10 employees. The company has raised $2.05M across two funding rounds from two investors. EpiTech MAG ceased operations in September 2022.
Business overview
EpiTech MAG develops a noninvasive medical device and method for the treatment of dry eye syndrome. Its proprietary technology, Viveye, is based on repetitive magnetic stimulation, utilizing targeted magnetic fields to stimulate the peripheral branches of the trigeminal nerve. This aims to reinforce the ocular surface's structural integrity, providing a zero-contact, affordable, and easily adopted procedure for long-lasting relief from dry eye symptoms. The company operates within the Health Tech & Life Sciences sector, specifically focusing on Medical Devices and Medical Treatment & Therapeutics, serving the healthcare provider market globally.
Log in to access full profile ›Company Intelligence Q&A
- What is EpiTech MAG's core technology?
- EpiTech MAG's core technology is Viveye, a noninvasive ocular neurostimulation therapy based on repetitive magnetic stimulation. It uses targeted magnetic fields to stimulate the peripheral branches of the trigeminal nerve to treat dry eye syndrome.
- When was EpiTech MAG founded?
- EpiTech MAG was founded in March 2015.
- What is the current operational status of EpiTech MAG?
- EpiTech MAG is non-active and ceased to operate in September 2022.
- Who is a co-founder of EpiTech MAG?
- Itzik Ronen is a co-founder and VP R&D at EpiTech MAG.
- What was the total capital raised by EpiTech MAG?
- EpiTech MAG raised a total of $2.05M across two funding rounds.